Amylyx Pharmaceuticals (AMLX) Competitors $4.05 +0.09 (+2.27%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMLX vs. RCKT, BCYC, AVDL, SEPN, COLL, ZYME, BCAX, GYRE, PSTX, and COGTShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Septerna (SEPN), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Bicara Therapeutics (BCAX), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Septerna Collegium Pharmaceutical Zymeworks Bicara Therapeutics Gyre Therapeutics Poseida Therapeutics Cogent Biosciences Rocket Pharmaceuticals (NASDAQ:RCKT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Do insiders & institutionals have more ownership in RCKT or AMLX? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 28.5% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor RCKT or AMLX? In the previous week, Rocket Pharmaceuticals had 9 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 15 mentions for Rocket Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Rocket Pharmaceuticals' score of 0.69 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor RCKT or AMLX? Rocket Pharmaceuticals received 357 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 73.17% of users gave Rocket Pharmaceuticals an outperform vote while only 66.00% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRocket PharmaceuticalsOutperform Votes39073.17% Underperform Votes14326.83% Amylyx PharmaceuticalsOutperform Votes3366.00% Underperform Votes1734.00% Is RCKT or AMLX more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of -36.97% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -62.62% -54.17% Amylyx Pharmaceuticals -17.86%-36.97%-29.61% Which has preferable valuation and earnings, RCKT or AMLX? Amylyx Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$245.60M-$2.75-4.20Amylyx Pharmaceuticals$196.49M1.41$49.27M-$3.82-1.06 Which has more risk & volatility, RCKT or AMLX? Rocket Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.68, indicating that its share price is 168% less volatile than the S&P 500. Do analysts rate RCKT or AMLX? Rocket Pharmaceuticals currently has a consensus price target of $48.80, indicating a potential upside of 322.15%. Amylyx Pharmaceuticals has a consensus price target of $7.33, indicating a potential upside of 81.07%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Amylyx Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.56 SummaryRocket Pharmaceuticals beats Amylyx Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$277.62M$6.57B$5.07B$9.08BDividend YieldN/A2.97%4.87%4.21%P/E Ratio-1.0610.5999.0517.15Price / Sales1.41195.041,121.17116.80Price / Cash7.3057.1641.5237.88Price / Book0.635.104.754.78Net Income$49.27M$151.51M$119.33M$225.60M7 Day Performance-1.70%-2.13%-1.86%-1.23%1 Month Performance-22.64%-3.14%11.40%3.07%1 Year Performance-70.97%11.53%30.26%16.48% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals4.2412 of 5 stars$4.05+2.3%$7.33+81.1%-70.7%$277.62M$196.49M-1.06200Short Interest ↓News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8481 of 5 stars$12.04+0.2%$51.00+323.6%-58.6%$1.10BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.6057 of 5 stars$15.51+12.3%$36.00+132.1%-18.8%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6696 of 5 stars$10.93+5.2%$24.43+123.5%-24.0%$1.05B$138.16M-13.15154Positive NewsSEPNSepterna2.2229 of 5 stars$22.44+0.2%$43.67+94.6%N/A$996.34MN/A0.00N/ACOLLCollegium Pharmaceutical3.845 of 5 stars$30.45+1.2%$42.60+39.9%-0.4%$982.01M$599.25M12.97210News CoveragePositive NewsZYMEZymeworks2.8279 of 5 stars$13.93+10.7%$18.83+35.2%+52.5%$959.50M$76.01M-9.25290Analyst ForecastNews CoverageGap DownBCAXBicara TherapeuticsN/A$17.62+0.7%$43.00+144.0%N/A$958.81MN/A0.0032Gap DownGYREGyre Therapeutics0.6051 of 5 stars$10.16+5.4%N/A-61.2%$950.17M$105.03M0.0040News CoveragePositive NewsPSTXPoseida Therapeutics3.7579 of 5 stars$9.51flat$9.50-0.1%+193.5%$929.79M$64.70M-15.10260Positive NewsCOGTCogent Biosciences1.95 of 5 stars$8.40+3.1%$14.83+76.6%+51.9%$927.86MN/A-3.2980 Related Companies and Tools Related Companies Rocket Pharmaceuticals Competitors Bicycle Therapeutics Competitors Avadel Pharmaceuticals Competitors Septerna Competitors Collegium Pharmaceutical Competitors Zymeworks Competitors Bicara Therapeutics Competitors Gyre Therapeutics Competitors Poseida Therapeutics Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMLX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMLX Stock Alerts